1. Home
  2. AMAL vs AVLN Comparison

AMAL vs AVLN Comparison

Compare AMAL & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amalgamated Financial Corp. (DE)

AMAL

Amalgamated Financial Corp. (DE)

HOLD

Current Price

$46.78

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Avalyn Pharma Inc. Common Stock

AVLN

Avalyn Pharma Inc. Common Stock

HOLD

Current Price

$23.55

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMAL
AVLN
Founded
1923
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.3B
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
AMAL
AVLN
Price
$46.78
$23.55
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$55.33
★ $61.80
AVG Volume (30 Days)
204.0K
★ 272.1K
Earning Date
10-22-2026
11-25-2026
Dividend Yield
★ 1.44%
N/A
EPS Growth
N/A
★ N/A
EPS
★ 1.99
N/A
Revenue
N/A
N/A
Revenue This Year
$14.45
N/A
Revenue Next Year
$6.56
N/A
P/E Ratio
$23.69
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$26.03
$22.68
52 Week High
$51.59
$40.17

Technical Indicators

Market Signals
Indicator
AMAL
AVLN
Relative Strength Index (RSI) 44.97 29.42
Support Level $46.34 N/A
Resistance Level $48.50 $30.45
Average True Range (ATR) 1.05 1.54
MACD 0.00 -0.10
Stochastic Oscillator 44.54 12.03

Price Performance

Historical Comparison
AMAL
AVLN

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.

About AVLN Avalyn Pharma Inc. Common Stock

Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.

Share on Social Networks: